Phase IIb randomized trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), a targeted oncolytic vaccinia virus, plus best supportive care (BSC) versus BSC alone in patients with advanced hepatocellular carcinoma who have failed sorafenib treatment (TRAVERSE).
Jeong Heo
No relevant relationships to disclose
Yee Chao
No relevant relationships to disclose
Derek J. Jonker
No relevant relationships to disclose
Ari David Baron
No relevant relationships to disclose
Francois Habersetzer
No relevant relationships to disclose
James Burke
Employment or Leadership Position - Jennerex Biotherapeutics
Stock Ownership - Jennerex Biotherapeutics
Caroline Breitbach
Employment or Leadership Position - Jennerex Biotherapeutics
Stock Ownership - Jennerex Biotherapeutics
Richard H. Patt
Consultant or Advisory Role - Jennerex Biotherapeutics
Riccardo Lencioni
Consultant or Advisory Role - Jennerex Biotherapeutics
Michel Homerin
Employment or Leadership Position - Transgene
Stock Ownership - Transgene
Jean-Marc Limacher
Employment or Leadership Position - Transgene
Stock Ownership - Transgene
Monika Lusky
Employment or Leadership Position - Transgene
Stock Ownership - Transgene
Theresa Hickman
Employment or Leadership Position - Jennerex Biotherapeutics
Stock Ownership - Jennerex Biotherapeutics
Lara Longpre
Employment or Leadership Position - Jennerex Biotherapeutics
Stock Ownership - Jennerex Biotherapeutics
David H. Kirn
Employment or Leadership Position - Jennerex Biotherapeutics
Stock Ownership - Jennerex Biotherapeutics